Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Suspended 1Recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 17Burkitt Lymphoma 16Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 4Recurrence 3Lymphoma, Large B-Cell, Diffuse 2Leukemia 2Philadelphia Chromosome 1Neoplasm, Residual 1Lymphoma, B-Cell 1Lymphoma 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Hematologic Neoplasms 1Blast Crisis 1

Interventions

Cyclophosphamide 254fludarabine phosphate 165Cytarabine 160Methotrexate 128Busulfan 115Filgrastim 111fludarabine 102Peripheral Blood Stem Cell Transplantation 96Rituximab 94Antilymphocyte Serum 83Etoposide 81Cyclosporine 75Tacrolimus 74Mycophenolic Acid 73Whole-Body Irradiation 72Radiotherapy 70Melphalan 66Vincristine 55Dexamethasone 54Granulocyte Colony-Stimulating Factor 50Methylprednisolone 48Azacitidine 44Alemtuzumab 42Imatinib Mesylate 41Clofarabine 41sargramostim 40Idarubicin 36Daunorubicin 36Cord Blood Stem Cell Transplantation 36Thiotepa 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Leukemia × Inotuzumab Ozogamicin × Clear all
NCT05645718 2026-05-19

Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia

M.D. Anderson Cancer Center

Phase 2 Recruiting
27 enrolled
Other hematologic neoplasm

Leukemia

NCT04747912 2026-03-30

Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)

University of Chicago

Phase 2 Suspended
25 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡